Search | OpenScholar

Search results

818 results found

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12:346-56.

Publication: Journal Article

Hauser, RA, A Hsu, S Kell, AJ Espay, K Sethi, M Stacy, W Ondo, M O’Connell, and S Gupta. 2013. “Extended-Release Carbidopa-Levodopa (IPX066) Compared With Immediate-Release Carbidopa-Levodopa in Patients With Parkinson’s Disease and Motor Fluctuations: A Phase 3 Randomised, Double-Blind Trial. Lancet Neurol 2013;12:346-56.”. Lancet Neurol.

Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 2012;18:370-6.

Publication: Journal Article

Rascol, O, J Bronzova, RA Hauser, AE Lang, C Sampaio, A Theeuwes, and SV Van De Witte. 2012. “Pardoprunox As Adjunct Therapy to Levodopa in Patients With Parkinson’s Disease Experiencing Motor Fluctuations: Results of a Double-Blind, Randomized, Placebo-Controlled, Trial. Parkinsonism Relat Disord 2012;18:370-6.”. Parkinsonism Relat Disord.

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.

Publication: Journal Article

Hersh, BP, NL Earl, RA Hauser, and M Stacy. 2010. “Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson’s Disease Patients With Motor Fluctuations.”. Mov Disord.

Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations.

Publication: Journal Article

Colosimo, C, P Martinez-Martin, G Fabbrini, RA Hauser, M Merello, J Miyasaki, W Poewe, et al. 2010. “Task Force Report on Scales to Assess Dyskinesia in Parkinson’s Disease: Critique and Recommendations.”. Mov Disord.

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.

Publication: Journal Article

Rascol, O, P Barone, RA Hauser, Y Mizuno, W Poewe, AH Schapira, L Salin, M Sohr, and C Debieuvre. 2010. “Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson’s Disease.”. Mov Disord.

The independent influence of apathy and depression on cognitive functioning in Parkinson's disease

Publication: Journal Article

Butterfield, LC, CR Cimino, LE Oelke, RA Hauser, and J Sanchez-Ramos. 2010. “The Independent Influence of Apathy and Depression on Cognitive Functioning in Parkinson’s Disease”. Neuropsychology.

TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Publication: Journal Article

Hauser, RA, MF Lew, HI Hurtig, WG Ondo, J Wojcieszek, and CJ Fitzer-Attas. 2009. “TEMPO Open-Label Study Group. Long-Term Outcome of Early versus Delayed Rasagiline Treatment in Early Parkinson’s Disease.”. Mov Disord.

Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 2011;77:767-74.

Publication: Journal Article

Schapira, AH, P Barone, RA Hauser, Y Mizuno, O Rascol, M Busse, L Salin, N Juhel, and . 2011. “Extended-Release Pramipexole in Advanced Parkinson Disease: A Randomized Controlled Trial. Neurology 2011;77:767-74.”. Neurology.

SPECT brain imaging in patients with suspected Parkinsonian syndromes.

Publication: Journal Article

Hauser, RA, and DG Grosset. 2012. “SPECT Brain Imaging in Patients With Suspected Parkinsonian Syndromes.”. J Neuroimaging.

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.

Publication: Journal Article

Olanow, CW, RA Hauser, J Jankovic, W Langston, A Lang, W Poewe, E Tolosa, et al. 2008. “A Randomized, Double-Blind, Placebo-Controlled, Delayed Start Study to Assess Rasagiline As a Disease Modifying Therapy in Parkinson’s Disease (the ADAGIO Study): Rationale, Design, and Baseline Characteristics.”. Mov Disord.